immune repertoire sequencing
Adaptive Biotechnologies Gets IVDR Class C Certification for ClonoSeq Assay
The certification makes the ClonoSeq assay available to EU patients and enables Adaptive to process EU clinical trial samples in its US laboratory.
Adaptive Biotechnologies Q2 Revenues Drop 12 Percent as MRD Revenues Soar
The Seattle-based company saw 36 percent growth in its minimal residual disease business while making significant progress in curbing operating expenses.
Breast Cancer Study Highlights Germline Genetic Influence on Tumor Subtype, Aggressiveness
Investigators saw relationships between germline epitope burdens in frequently amplified driver genes and immunoediting-related breast cancer features.
Xenotransplant Responses, Interactions Unraveled With Multiomic Analyses
Researchers tracked molecular consequences of transplanting genetically modified pig hearts into two brain-dead recipients, identifying distinct effects in each.
Adaptive Biotechnologies Expects Growth From FDA Panel MRD Vote, Cuts Staff by 7 Percent in Q1
Premium
Q1 revenues grew 11 percent year over year, to $41.9 million from $37.6 million, slightly less than the 12 percent increase the company had anticipated.